These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33193355)

  • 21. CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease.
    de Masson A; Bouaziz JD; Le Buanec H; Robin M; O'Meara A; Parquet N; Rybojad M; Hau E; Monfort JB; Branchtein M; Michonneau D; Dessirier V; Sicre de Fontbrune F; Bergeron A; Itzykson R; Dhédin N; Bengoufa D; Peffault de Latour R; Xhaard A; Bagot M; Bensussan A; Socié G
    Blood; 2015 Mar; 125(11):1830-9. PubMed ID: 25605369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation.
    Gao L; Zhang Y; Hu B; Liu J; Kong P; Lou S; Su Y; Yang T; Li H; Liu Y; Zhang C; Gao L; Zhu L; Wen Q; Wang P; Chen X; Zhong J; Zhang X
    J Clin Oncol; 2016 Aug; 34(24):2843-50. PubMed ID: 27400949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome.
    Zecca M; Prete A; Rondelli R; Lanino E; Balduzzi A; Messina C; Fagioli F; Porta F; Favre C; Pession A; Locatelli F;
    Blood; 2002 Aug; 100(4):1192-200. PubMed ID: 12149197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD56bright CD16- natural killer cells as an important regulatory mechanism in chronic graft-
    Lauener M; AzadPour S; Abdossamadi S; Parthasarathy V; Ng B; Ostroumov E; Cuvelier GDE; Levings MK; MacDonald KN; Kariminia A; Schultz KR
    Haematologica; 2023 Mar; 108(3):761-771. PubMed ID: 36200416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study.
    Cuvelier GDE; Ng B; Abdossamadi S; Nemecek ER; Melton A; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; Ostroumov E; Schultz KR
    Blood Adv; 2023 Jul; 7(14):3612-3623. PubMed ID: 36219586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.
    Dander E; Balduzzi A; Zappa G; Lucchini G; Perseghin P; Andrè V; Todisco E; Rahal D; Migliavacca M; Longoni D; Solinas G; Villa A; Berti E; Mina PD; Parma M; Allavena P; Biagi E; Rovelli A; Biondi A; D'Amico G
    Transplantation; 2009 Dec; 88(11):1261-72. PubMed ID: 19996925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.
    Jacobson CA; Sun L; Kim HT; McDonough SM; Reynolds CG; Schowalter M; Koreth J; Cutler CS; Ho VT; Alyea EP; Armand P; Blazar BR; Soiffer RJ; Antin JH; Ritz J; Sarantopoulos S
    Biol Blood Marrow Transplant; 2014 May; 20(5):668-75. PubMed ID: 24462743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.
    Sarantopoulos S; Stevenson KE; Kim HT; Washel WS; Bhuiya NS; Cutler CS; Alyea EP; Ho VT; Soiffer RJ; Antin JH; Ritz J
    Blood; 2011 Feb; 117(7):2275-83. PubMed ID: 21097674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD38 Deficiency Ameliorates Chronic Graft-
    Martínez-Blanco Á; Domínguez-Pantoja M; Botía-Sánchez M; Pérez-Cabrera S; Bello-Iglesias N; Carrillo-Rodríguez P; Martin-Morales N; Lario-Simón A; Pérez-Sánchez-Cañete MM; Montosa-Hidalgo L; Guerrero-Fernández S; Longobardo-Polanco VM; Redondo-Sánchez S; Cornet-Gomez A; Torres-Sáez M; Fernández-Ibáñez A; Terrón-Camero L; Andrés-León E; O'Valle F; Merino R; Zubiaur M; Sancho J
    Front Immunol; 2021; 12():713697. PubMed ID: 34504495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution.
    Abdel-Azim H; Elshoury A; Mahadeo KM; Parkman R; Kapoor N
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1437-1446. PubMed ID: 28495643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reconstitution of Th17, Tc17 and Treg cells after paediatric haematopoietic stem cell transplantation: Impact of interleukin-7.
    Kielsen K; Ryder LP; Lennox-Hvenekilde D; Gad M; Nielsen CH; Heilmann C; Ifversen M; Pedersen AE; Müller K
    Immunobiology; 2018 Feb; 223(2):220-226. PubMed ID: 29033080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High frequencies of CD62L⁺ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation.
    Lu SY; Liu KY; Liu DH; Xu LP; Huang XJ
    Clin Exp Immunol; 2011 Aug; 165(2):264-77. PubMed ID: 21635226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-Negative T Cell Levels Correlate with Chronic Graft-versus-Host Disease Severity.
    Hillhouse EE; Thiant S; Moutuou MM; Lombard-Vadnais F; Parat R; Delisle JS; Ahmad I; Roy DC; Guimond M; Roy J; Lesage S
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):19-25. PubMed ID: 30244108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alloantigen-specific regulatory T cells prevent experimental chronic graft-versus-host disease by simultaneous control of allo- and autoreactivity.
    Sagoo P; Ratnasothy K; Tsang Y; Barber LD; Noble A; Lechler RI; Lombardi G
    Eur J Immunol; 2012 Dec; 42(12):3322-33. PubMed ID: 22996319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia.
    Kuzmina Z; Greinix HT; Weigl R; Körmöczi U; Rottal A; Frantal S; Eder S; Pickl WF
    Blood; 2011 Feb; 117(7):2265-74. PubMed ID: 21063025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.
    Imanguli MM; Cowen EW; Rose J; Dhamala S; Swaim W; Lafond S; Yagi B; Gress RE; Pavletic SZ; Hakim FT
    Leukemia; 2014 Oct; 28(10):2016-27. PubMed ID: 24577531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.
    Kawano Y; Kim HT; Matsuoka K; Bascug G; McDonough S; Ho VT; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J
    Blood; 2011 Nov; 118(18):5021-30. PubMed ID: 21900196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation.
    Lertkovit O; Anurathapan U; Hongeng S; Thokanit NS; Pakakasama S
    Int J Hematol; 2021 Apr; 113(4):556-565. PubMed ID: 33385291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced flowcytometric analysis of regulatory T cells: CD127 downregulation early post stem cell transplantation and altered Treg/CD3(+)CD4(+)-ratio in severe GvHD or relapse.
    Bremm M; Huenecke S; Lehrnbecher T; Ponstingl E; Mueller R; Heinze A; Bug G; Quaiser A; Kapinsky M; Brehm C; Bader P; Schneider G; Klingebiel T; Koehl U
    J Immunol Methods; 2011 Oct; 373(1-2):36-44. PubMed ID: 21839739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.